trimetrexate has been researched along with Acute Lymphoid Leukemia in 8 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We established a novel human acute lymphoblastic leukemia cell line made resistant to two folate analogues, trimetrexate (TMQ) and N10-propargyl-5,8-dideazafolic acid (CB3717), by sequential exposure of the 200-fold TMQ-resistant cells (MOLT-3/TMQ200) to CB3717." | 1.28 | A human leukemia cell line made resistant to two folate analogues, trimetrexate and N10-propargyl-5,8-dideazafolic acid (CB3717). ( Miyachi, H; Ohnuma, T; Sekiguchi, S; Takemura, Y, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lacerda, JF | 1 |
| Göker, E | 3 |
| Kheradpour, A | 2 |
| Dennig, D | 1 |
| Elisseyeff, Y | 2 |
| Jagiello, C | 1 |
| O'Reilly, RJ | 1 |
| Bertino, JR | 2 |
| Berman, E | 2 |
| Lin, JT | 1 |
| Tong, WP | 1 |
| Kobayashi, H | 2 |
| Dorai, T | 1 |
| Holland, JF | 2 |
| Ohnuma, T | 4 |
| Li, XK | 1 |
| Trippett, T | 1 |
| Schlemmer, S | 1 |
| Wachter, M | 1 |
| Steinherz, P | 1 |
| Tan, C | 1 |
| Wright, JE | 1 |
| Rosowsky, A | 1 |
| Takemura, Y | 2 |
| Miyachi, H | 1 |
| Sekiguchi, S | 1 |
| Pappo, A | 1 |
| Dubowy, R | 1 |
| Ravindranath, Y | 1 |
| Alvarado, C | 1 |
| Rao, S | 1 |
| Whitehead, VM | 1 |
| Vega, R | 1 |
| Kamen, B | 1 |
| Vietti, T | 1 |
2 trials available for trimetrexate and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
A phase II study of continuous infusion of trimetrexate in patients with refractory acute leukemia.
Topics: Adult; Aged; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Precursor Cell | 1995 |
Phase II trial of trimetrexate in the treatment of recurrent childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Topics: Adolescent; Child; Child, Preschool; Drug Administration Schedule; Female; Humans; Infant; Infusions | 1990 |
6 other studies available for trimetrexate and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Selective treatment of SCID mice bearing methotrexate-transport-resistant human acute lymphoblastic leukemia tumors with trimetrexate and leucovorin protection.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Drug Resistance; Huma | 1995 |
Cleavage of human MDR1 mRNA by a hammerhead ribozyme.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Binding Sites; Codon; Drug R | 1993 |
Expression of dihydrofolate reductase and multidrug resistance genes in trimetrexate-resistant human leukemia cell lines.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Northern; Blotting, Southern; Car | 1993 |
Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Biological Transport; Child; Child, Preschool; Drug Resistance; Female; Hum | 1992 |
N10-propargyl-5,8-dideazafolic acid (CB3717): inhibitory effects on human leukemia cell lines resistant to methotrexate or trimetrexate.
Topics: Antineoplastic Agents; Cell Division; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Dr | 1992 |
A human leukemia cell line made resistant to two folate analogues, trimetrexate and N10-propargyl-5,8-dideazafolic acid (CB3717).
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Division; Cell | 1991 |